

M.M. Hoepfer has received speaker and/or consultant fees from Actelion, Bayer, Gilead, GSK, Lilly, Novartis and Pfizer.

M. Halank has received honoraria and travel grants from Actelion, Bayer Schering Pharma AG, Encysive, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics.

H. Wilkens has received honoraria for speaking at conferences and/or consultations from Actelion, Bayer, GSK, Lilly, Pfizer und United Therapeutics.

G. Weimann was a full-time employee of Bayer HealthCare from 2005–2011.

I. Gebert is currently an employee of Bayer HealthCare, the sponsor of the study described.

H.H. Leuchte has served on the advisory boards of Actelion, GlaxoSmithKline, Lilly and Pfizer and has received lecture fees from Actelion, Bayer, GlaxoSmithKline, Lilly and Pfizer and grant support from Actelion and MondoBiotech.

J. Behr has received fees for speaking from Actelion, Altana, Bayer-Schering, Boehringer-Ingelheim, Encysive, GSK, Pfizer, Lilly, Nycomed, InterMune, Novartis and MSD; has served as consultant/advisor for Actelion, Bayer-Schering-Pharma, Lilly, Pari-Pharma, GSK, Pfizer and Gilead; has received research grants from Actelion, Bayer-Schering and Pari-Pharma; and was sponsored by Actelion, Boehringer-Ingelheim, AstraZeneca and Bayer to attend international and national congresses.